Noninfectious UveitisMUMIPNCT07885501
The Microbiome in Uveitis and Pediatric Inflammatory Diseases
An observational study of Noninfectious Uveitis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
Trial summary
Chronic, noninfectious uveitis in children, associated with various systemic inflammatory diseases, carries a high risk of vision loss. Intestinal dysbiosis and the translocation of bacterial peptidoglycans (PG) that activate innate receptors recognizing PG could represent a common initiating mechanism, independent of… Read more about this study
- Who is it for?
- Ages 1 day to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Noninfectious Uveitis
- How many people
- 500 participants
- Where
- 1 siteFrance
- Study dates
- Nov 2026to Dec 2028
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 day to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: * Confirmed infectious uveitis (bacterial, viral, fungal, parasitic) * Participation in an interventional clinical trial affecting the microbiome or immune system
Who may be able to join
- Patients under the age of 18 being treated at Robert-Debré Hospital
- Patients being treated for noninfectious uveitis, or with pediatric inflammatory diseases without uveitis (connective tissue disorders, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitides).
- The child and his or her parents have no objection to participating in the study
- Siblings of patients (family controls) or other healthy controls (children of hospital staff)
Who cannot join
- -
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
Hôpital Robert Debré - APHP
Paris, 75019
Ulrich Meinzer, PhD, +33 1 40 03 25 99, ulrich.meizer@aphp.fr
About this study
Official title: The Gut Microbiota in Uveitis and Pediatric Inflammatory Diseases: Identification of the Fecal Peptidoglycan Signature
Chronic, noninfectious uveitis in children, associated with various systemic inflammatory diseases, carries a high risk of vision loss. Intestinal dysbiosis and the translocation of bacterial peptidoglycans (PG) that activate innate receptors recognizing PG could represent a common initiating mechanism, independent of the underlying disease. Studying these biological signatures in comparative cohorts could lead to a better understanding of the onset of uveitis and the development of targeted diagnostic and therapeutic strategies.
Read the detailed description
The objectives of this project are to characterize the peptidoglycan (PG) signature in healthy children and in the context of pediatric noninfectious uveitis; to compare the peptidoglycan signatures of patients with noninfectious uveitis to those with pediatric inflammatory diseases without uveitis; and to determine the correlation between these PG signatures, microbiota composition, and disease parameters in the context of uveitis.
Participants will be informed about the study during their routine follow-up visits.
- A stool collection kit, containing all necessary supplies and instructions, will be provided to families.
- Samples will be collected at the hospital or at home and then sent directly to the laboratory by mail.
- For patients, blood samples collected as part of routine care (blood draws for routine laboratory tests) and of which a portion is not used will be collected to establish a biobank dedicated to research.
These procedures do not require any additional medical procedures or visits beyond routine follow-up.
- Conditions
- Noninfectious Uveitis
- Keywords
- pediatric inflammatory diseases without ocular involvement, gut microbiota
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| patients with noninfectious uveitis | including pediatric connective tissue disorders, granulomatosis, idiopathic juvenile arthritis without uveitis, pediatric vasculitis, and chronic inflammatory bowel diseases. These conditions were selected because of their inflammatory and/or autoimmune nature, making it possible to determine whether fecal peptidoglycan signatures | |
| patients with another inflammatory disease | without uveitis (connective tissue disease, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitis, chronic inflammatory bowel disease) | |
| healthy children living in the same household as those who are sick | Siblings of patients or children of hospital staff, who may be included as healthy control groups |
What is being measured
The primary outcome is the main question the study is designed to answer.
fecal peptidoglycans
the composition and relative abundance of fecal PG fragments in children with uveitis compared to healthy children.
Measured: Day 1
Secondary outcomes (1)
Gut Microbiome
- Correlations between the peptidoglycans and the gut microbiota, as determined by sequencing.
- Analysis of fecal microRNAs (miRNAs) and their correlations with the peptidoglycans and the microbiota.
- Analysis of associations between the peptidoglycans and the microbiota, miRNAs, and clinical parameters: uveitis activity, ophthalmic complications, and patient metadata.
- Comparison with the additional control group (non-ocular inflammatory diseases) to identify signatures specific to uveitis versus those associated with a systemic inflammatory condition.
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Noninfectious UveitisStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Ulrich Meinzer, PhD, Study chair, APHP
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07885501
- Sponsor's protocol ID
- APHP260740
- Other IDs
- 2026-A01372-49
- Acronym
- MUMIP
- Status last verified
- Oct 2026
- First submitted
- 13 Oct 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Gut Microbiota in Uveitis and Pediatric Inflammatory Diseases: Identification of the Fecal Peptidoglycan Signature
- ClinicalTrials.gov ID
- NCT07885501
- Acronym / sponsor ID
- MUMIP / APHP260740
- Conditions
- Noninfectious Uveitis
- Keywords
- pediatric inflammatory diseases without ocular involvement, gut microbiota
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 21 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic, noninfectious uveitis in children, associated with various systemic inflammatory diseases, carries a high risk of vision loss. Intestinal dysbiosis and the translocation of bacterial peptidoglycans (PG) that activate innate receptors recognizing PG could represent a common initiating mechanism, independent of the underlying disease. Studying these biological signatures in comparative cohorts could lead to a better understanding of the onset of uveitis and the development of targeted diagnostic and therapeutic strategies.
Detailed description
The objectives of this project are to characterize the peptidoglycan (PG) signature in healthy children and in the context of pediatric noninfectious uveitis; to compare the peptidoglycan signatures of patients with noninfectious uveitis to those with pediatric inflammatory diseases without uveitis; and to determine the correlation between these PG signatures, microbiota composition, and disease parameters in the context of uveitis.
Participants will be informed about the study during their routine follow-up visits.
- A stool collection kit, containing all necessary supplies and instructions, will be provided to families.
- Samples will be collected at the hospital or at home and then sent directly to the laboratory by mail.
- For patients, blood samples collected as part of routine care (blood draws for routine laboratory tests) and of which a portion is not used will be collected to establish a biobank dedicated to research.
These procedures do not require any additional medical procedures or visits beyond routine follow-up.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Day
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| patients with noninfectious uveitis | – | –including pediatric connective tissue disorders, granulomatosis, idiopathic juvenile arthritis without uveitis, pediatric vasculitis, and chronic inflammatory bowel diseases. These conditions were selected because of their inflammatory and/or autoimmune nature, making it possible to determine whether fecal peptidoglycan signatures |
| patients with another inflammatory disease | – | –without uveitis (connective tissue disease, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitis, chronic inflammatory bowel disease) |
| healthy children living in the same household as those who are sick | – | –Siblings of patients or children of hospital staff, who may be included as healthy control groups |
Who may qualify
- Ages
- 1 day to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- * Confirmed infectious uveitis (bacterial, viral, fungal, parasitic) * Participation in an interventional clinical trial affecting the microbiome or immune system
Key inclusion criteria (4 listed)
- Patients under the age of 18 being treated at Robert-Debré Hospital
- Patients being treated for noninfectious uveitis, or with pediatric inflammatory diseases without uveitis (connective tissue disorders, granulomatosis, juvenile idiopathic arthritis, pediatric vasculitides).
- The child and his or her parents have no objection to participating in the study
- Siblings of patients (family controls) or other healthy controls (children of hospital staff)
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
fecal peptidoglycans
Time frame: Day 1
the composition and relative abundance of fecal PG fragments in children with uveitis compared to healthy children.
1 secondary outcome
Gut Microbiome
Time frame: Day 1
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Related trials for Noninfectious Uveitis
Not yet recruitingPhase 2
A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)
Noninfectious Intermediate, Posterior, or Panuveitis
Active, not recruitingPhase 3
A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis
Non-infectious Anterior Uveitis
Not yet recruitingObservational study
Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant
Noninfectious Posterior Uveitis, Uveitis, Posterior
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ulrich Meinzer, PhD study chair
APHP
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Noninfectious Uveitis, run by Assistance Publique - Hôpitaux de Paris at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ulrich Phd Meinzer, PhD (+33 140 03 25 99, ulrich.meinzer@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
fecal peptidoglycans (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.